Skip to main content

Management of adnexal mass.

Publication ,  Journal Article
Myers, ER; Bastian, LA; Havrilesky, LJ; Kulasingam, SL; Terplan, MS; Cline, KE; Gray, RN; McCrory, DC
Published in: Evid Rep Technol Assess (Full Rep)
February 2006

OBJECTIVES: To assess diagnostic strategies for distinguishing benign from malignant adnexal masses. DATA SOURCES: MEDLINE(R) and reference lists of recent reviews; discharge data from the Nationwide Inpatient Sample. REVIEW METHODS: The major diagnostic methods evaluated were bimanual pelvic examination, ultrasound (morphology and Doppler velocimetry), MRI, CT, FDG-PET, CA-125, and scoring systems that incorporated multiple clinical, laboratory, and radiologic findings. Meta-analysis using a random-effects model was used to estimate pooled sensitivity and specificity for discriminating benign from malignant. We reviewed evidence for followup strategies for masses considered benign, and for adverse outcomes of diagnostic surgery. We also reviewed published models of the natural history of ovarian cancer and compared the impact of assumptions about natural history on outcomes. RESULTS: The majority of studies did not describe whether patients presented with asymptomatic masses detected through screening or with symptoms. Prevalence of malignant masses in a U.S. postmenopausal screening population was approximately 0.1 percent, while benign masses were found in 0.8 to 1.8 percent of women. Pooled (a) sensitivity and (b) specificity were: bimanual exam (a) 0.45, (b) 0.90; ultrasound morphology scores (a) 0.86 to 0.91, (b) 0.68 to 0.83; Doppler resistive index (a) 0.72, (b) 0.90; pulsatility index (a) 0.80, (b) 0.73; maximum systolic velocity (a) 0.74, (b) 0.81; presence of vessels (a) 0.88, (b) 0.78; combined morphology and Doppler (a) 0.86, (b) 0.91; MRI (a) 0.91, (b) 0.88; CT (a) 0.90, (b) 0.75; FDG-PET (a) 0.67, (b) 0.79; and CA-125 (a) 0.78, (b) 0.78. Both sensitivity and specificity of CA-125 were better in postmenopausal than in premenopausal women. In modeled outcomes, combinations of imaging and CA-125 were both more sensitive and more specific than either alone. Performance of scoring systems in validation studies was consistently worse than in development studies; the highest demonstrated specificity observed was 0.91, with a concurrent sensitivity of 0.74. Evidence on followup strategies was sparse, although one large study provided good evidence for safely following unilocular cysts less than 10 cm in diameter. Overall complication rates in studies of surgically managed adnexal masses were low, but important clinical information was not reported. CONCLUSIONS: All diagnostic modalities showed trade-offs between sensitivity and specificity, but the available literature does not provide sufficient detail on relevant characteristics of study populations to allow confident estimation of the results of alternative diagnostic strategies. Although modeling studies may prove useful in evaluating diagnostic algorithms, further work is needed to explore the implications of uncertainty about the natural history of ovarian cancer.

Duke Scholars

Published In

Evid Rep Technol Assess (Full Rep)

ISSN

1530-4396

Publication Date

February 2006

Issue

130

Start / End Page

1 / 145

Location

United States

Related Subject Headings

  • United States
  • Ultrasonography, Doppler
  • Treatment Outcome
  • Sensitivity and Specificity
  • Pelvis
  • Ovarian Neoplasms
  • Middle Aged
  • Menopause
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Myers, E. R., Bastian, L. A., Havrilesky, L. J., Kulasingam, S. L., Terplan, M. S., Cline, K. E., … McCrory, D. C. (2006). Management of adnexal mass. Evid Rep Technol Assess (Full Rep), (130), 1–145.
Myers, Evan R., Lori A. Bastian, Laura J. Havrilesky, Shalini L. Kulasingam, Mishka S. Terplan, Kathryn E. Cline, Rebecca N. Gray, and Douglas C. McCrory. “Management of adnexal mass.Evid Rep Technol Assess (Full Rep), no. 130 (February 2006): 1–145.
Myers ER, Bastian LA, Havrilesky LJ, Kulasingam SL, Terplan MS, Cline KE, et al. Management of adnexal mass. Evid Rep Technol Assess (Full Rep). 2006 Feb;(130):1–145.
Myers, Evan R., et al. “Management of adnexal mass.Evid Rep Technol Assess (Full Rep), no. 130, Feb. 2006, pp. 1–145.
Myers ER, Bastian LA, Havrilesky LJ, Kulasingam SL, Terplan MS, Cline KE, Gray RN, McCrory DC. Management of adnexal mass. Evid Rep Technol Assess (Full Rep). 2006 Feb;(130):1–145.

Published In

Evid Rep Technol Assess (Full Rep)

ISSN

1530-4396

Publication Date

February 2006

Issue

130

Start / End Page

1 / 145

Location

United States

Related Subject Headings

  • United States
  • Ultrasonography, Doppler
  • Treatment Outcome
  • Sensitivity and Specificity
  • Pelvis
  • Ovarian Neoplasms
  • Middle Aged
  • Menopause
  • Humans
  • Female